



**BOOTH #78
REGISTER FOR
WORKSHOPS!**

PROGRAM

Program Book

Scientific program by Miltenyi Biotec at ISCT 2019

ISCT 2019 Annual Meeting

May 29 – June 1, 2019

Melbourne Convention and Exhibition Centre

Melbourne, Australia

OPENING REMARKS

Dear ISCT Attendees,

Welcome to the 2019 Annual Meeting in Melbourne. It is a pleasure to see you again at this intriguing venue down under.

We are excited to share our latest updated and new developments with you. Meet us at booth #78 to learn more about the automated cell manufacturing platform CliniMACS Prodigy®, the MACSQuant® Tyto® Cell Sorter, and our comprehensive workflow solutions.

Listen to the experts in the Miltenyi Biotec Symposium and join us in our workshops to see the sophisticated CliniMACS Prodigy applications in action.

Looking forward to meeting you!

Your Miltenyi Biotec Team

Highlights at ISCT 2019

Symposium

Listen to three exciting talks giving insights into clinical applications and development of cell therapies.

Wednesday, May 29, 04:30–06:30 p.m.
Room MR219

CliniMACS Prodigy® Workshops

Join our live demonstrations of the CliniMACS Prodigy®. Learn how genetically modified T cells or stem cells and their derivatives can be manufactured in an automated, closed, and scalable system.

Thursday, May 30 & Friday, May 31
Room MR218

Come by booth #78 for the latest information on open slots and to register for the workshop.

Poster sessions

Find out about the latest scientific research and developments by Miltenyi Biotec.

Live demonstration

Come to our booth #78 for a demo of the MACSQuant® Tyto® Cell Sorter.

SYMPOSIUM

Cutting-edge manufacturing solutions for advanced cell therapies

Wednesday, May 29, 2019

04:30–06:30 p.m.

Room MR219

Chair

John Rasko, Prof., Ph.D.
Royal Prince Alfred Hospital
Camperdown, Australia



04:30–05:10 p.m. Development of automated protocols for the production of iPSC derived therapies

Amit Chandra, Ph.D.
Innovation Supervisor Cell
Therapy, Yposkesi SAS
Corbeil-Essonnes, France

05:10–05:50 p.m. Automated manufacturing of chimeric antigen receptor T cells

Lin Yang, Prof., Ph.D.
PersonGen BioTherapeutics
(Suzhou) Co., Ltd.
Suzhou, China

05:50–06:30 p.m. Point of care manufacturing of anti-CD19 CAR T cells for lymphoma

Marcos de Lima, Prof., M.D.
University Hospitals Cleveland
Medical Center
Cleveland, USA

Chair

John Rasko, Prof., Ph.D., is a pioneer in the application of adult stem cells and genetic therapy. Since 1999, he has directed the Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, and the Gene and Stem Cell Therapy Program, Centenary Institute, University of Sydney. He is the President of the International Society for Cell & Gene Therapy.

As a clinical hematologist, pathologist, and scientist, John Rasko has an international reputation in gene and stem cell therapy, experimental hematology, and molecular biology. In over 170 publications he has contributed to the understanding of stem cells and biology of blood cell development, gene therapy technologies, cancer causation and treatment, human genetic diseases and human ethics.

In 2018, the Board of the ABC honored him as the 60th Boyer Lecturer. He is the recipient of national (RCPA, RACP, ASBMB) and international awards in recognition of his commitment to excellence in medical research.

SYMPOSIUM SPEAKER



Amit Chandra, Ph.D., is Innovation Supervisor at the Cell Therapy Business Unit at Yposkesi SAS since January 2017. He joined the Business Unit to develop novel automation processes for the production of pluripotent stem cell therapy products. His expertise includes developing and validating novel equipment for use in a regulatory environment. Prior to this, Amit Chandra was the Engineering Team Leader for the Cell Therapy Manufacturing Facility based at Loughborough University Science and Enterprise Park (LUSEP). He worked in a multi-disciplinary team to set up and validate a novel facility incorporating an automated cell culture platform for autologous therapies with multiple patient samples. During his work as maxillofacial engineer at Nottingham University Hospitals NHS Trust Queens Medical Centre Campus, he gained clinical experience as well.

Notes



Lin Yang, Prof., Ph.D., is Distinguished Professor at the Cyrus Tang Hematology Center of Soochow University, China, and Adjunct Professor of the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center, USA. He is founder, chairman, and chief scientific officer of PersonGen BioTherapeutics (Suzhou) Co., Ltd., as well as chairman and CEO of PersonGen-Anke Cellular Therapeutics Co., Ltd. Lin Yang has published more than 70 research articles in recognized peer reviewed journals, such as Cancer Cell, Cancer Research, Oncogene, JBC, and Cancer Science. As a principle investigator, he plays a major role in the immunotherapy of CAR T cells and CAR NK cells in China, and has obtained impressive achievements in the industrialization and conducting clinical trials of CART cell therapy.

Notes



Marcos de Lima, Prof., M.D., is Director of Stem Cell Transplant and Hematologic Malignancies at the University Hospitals Cleveland Medical Center, and Professor of Medicine, Case Western Reserve University. He has extensive experience in developing and conducting clinical trials in the context of hematopoietic stem cell transplantation for myeloid malignancies. His research focuses on strategies to expand allogeneic transplantations into patients without HLA-identical siblings, the treatment and prevention of leukemia relapse after transplant, and the development of novel cellular therapy approaches to treating blood cancers.

Notes

WORKSHOPS

Room MR218

Take the opportunity to learn more about automated clinical-scale processing of T cells or adherent stem cells using the CliniMACS Prodigy®. Choose your preferred workshop time and register at booth #78.

Thursday, May 30

CliniMACS Prodigy® T Cell Transduction (TCT)

What is the secret of success of our CliniMACS Prodigy® T Cell Transduction Process? We give you an exciting live demonstration to explore the easiness and the benefits of fully automated and closed T cell processing.

11:00 a.m.–12:00 p.m.

01:45 p.m.–02:45 p.m.

03:30 p.m.–04:30 p.m.

Friday, May 31

CliniMACS Prodigy® Adherent Cell Culture System (ACC)

How to implement GMP-compliant and scalable manufacturing of adherent stem cells and their derivatives, such as PSCs, MSCs, and dopaminergic progenitors? Get hands-on experience in fully automated and closed manufacturing of adherent cells.

10:30 a.m.–11:30 a.m.

01:45 p.m.–02:45 p.m.

04:30 p.m.–05:30 p.m.

Notes

POSTER SESSIONS

Exhibition Centre

Standardized QC assays and large-scale expansion of pluripotent stem cells using an automated closed system

Presenter: Kathrin Godthardt
Poster number: 110
Presentation: Poster Session 1
Thursday, May 30, 2019
06:00 p.m.–07:30 p.m.

Efficient GMP-compliant expansion of mesenchymal stromal cells (MSCs) from umbilical cord, bone marrow, and adipose tissue using a closed cultivation system

Presenter: Kathrin Godthardt
Poster number: 256
Presentation: Poster Session 2
Friday, May 31, 2019
05:00 p.m.–06:30 p.m.

Notes



► [miltenyibiotec.com](https://www.miltenyibiotec.com)

Miltenyi Biotec GmbH | Friedrich-Ebert-Straße 68 | 51429 Bergisch Gladbach | Germany | Phone +49 2204 8306-0 | Fax +49 2204 85197
macs@miltenyibiotec.de | www.miltenyibiotec.com

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Image © Scott13/shutterstock.com

The statements and other contributions presented at the symposium and the views expressed therein are those of the attending experts and do not necessarily represent the policy or opinion of Miltenyi Biotec or any institution the respective expert may be associated with. Neither Miltenyi Biotec nor any of its directors or employees give any representation or warranty as to the reliability, accuracy, or completeness of the content thereof. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This notice must accompany any further distribution of this document.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use.

In the US, the CliniMACS Prodigy® T Cell Transduction Process is available for research use only. CliniMACS, CliniMACS Prodigy, MACS, the MACS logo, and MACSQuant Tyto are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2019 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.